These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 22535289)

  • 1. The rise and fall of ADHD child prescribing in Western Australia: lessons and implications.
    Whitely M
    Aust N Z J Psychiatry; 2012 May; 46(5):400-3. PubMed ID: 22535289
    [No Abstract]   [Full Text] [Related]  

  • 2. Central stimulants in the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adolescents. A naturalistic study of the prescription in Sweden, 1977-2007.
    Janols LO; Liliemark J; Klintberg K; von Knorring AL
    Nord J Psychiatry; 2009 Nov; 63(6):508-16. PubMed ID: 19958258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in the consumption of attention deficit hyperactivity disorder medications in Castilla y León (Spain): changes in the consumption pattern following the introduction of extended release methylphenidate.
    Treceño C; Martín Arias LH; Sáinz M; Salado I; García Ortega P; Velasco V; Jimeno N; Escudero A; Velasco A; Carvajal A
    Pharmacoepidemiol Drug Saf; 2012 Apr; 21(4):435-41. PubMed ID: 22253017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in the prescribing of stimulant medication for the treatment of Attention Deficit Hyperactivity Disorder in adults in New South Wales.
    New South Wales Department of Health
    N S W Public Health Bull; 2004; 15 Suppl 3():1-55. PubMed ID: 15448720
    [No Abstract]   [Full Text] [Related]  

  • 5. Prevalence of methylphenidate prescription among school-aged children in a Swiss population: increase in the number of prescriptions in the Swiss Canton of Vaud, from 2002 to 2005, and changes in patient demographics.
    Gumy C; Huissoud T; Dubois-Arber F
    J Atten Disord; 2010 Nov; 14(3):267-72. PubMed ID: 20484708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Innovations and recent trends in the treatment of ADHD.
    Madaan V; Kinnan S; Daughton J; Kratochvil CJ
    Expert Rev Neurother; 2006 Sep; 6(9):1375-85. PubMed ID: 17009924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment stabilization in children and adolescents with attention-deficit/hyperactivity disorder: data from the Netherlands.
    Sasané R; Hodgkins P; Meijer W
    Curr Med Res Opin; 2010 Nov; 26(11):2565-74. PubMed ID: 20863165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Massive variation in Ritalin prescribing.
    Gainsbury S
    Health Serv J; 2008 Jul; ():5. PubMed ID: 18705035
    [No Abstract]   [Full Text] [Related]  

  • 9. Managing attention-deficit/hyperactivity disorder in primary care: a systematic analysis of roles and challenges.
    Power TJ; Mautone JA; Manz PH; Frye L; Blum NJ
    Pediatrics; 2008 Jan; 121(1):e65-72. PubMed ID: 18166546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drugged-out toddlers. A new study documents an alarming increase in behavior-altering medication for preschoolers.
    Kalb C
    Newsweek; 2000 Mar; 135(10):53. PubMed ID: 10847892
    [No Abstract]   [Full Text] [Related]  

  • 11. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
    Chavez B; Sopko MA; Ehret MJ; Paulino RE; Goldberg KR; Angstadt K; Bogart GT
    Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attention-deficit/hyperactivity disorder: are we medicating for social disadvantage? (For).
    Isaacs D
    J Paediatr Child Health; 2006 Sep; 42(9):544-7. PubMed ID: 16925542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database.
    Winterstein AG; Gerhard T; Shuster J; Zito J; Johnson M; Liu H; Saidi A
    Ann Pharmacother; 2008 Jan; 42(1):24-31. PubMed ID: 18042808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the American Heart Association scientific statement on screening electrocardiograms and stimulant medications.
    Thomas PE; Carlo WF; Decker JA; Cannon BC; Kertesz NJ; Friedman RA; Kim JJ
    Arch Pediatr Adolesc Med; 2011 Feb; 165(2):166-70. PubMed ID: 21300657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attention-deficit/hyperactivity disorder: are we medicating for social disadvantage? (Against).
    Efron D
    J Paediatr Child Health; 2006 Sep; 42(9):548-51. PubMed ID: 16925543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paediatricians' decision making about prescribing stimulant medications for children with attention-deficit/hyperactivity disorder.
    Chow SJ; Sciberras E; Gillam LH; Green J; Efron D
    Child Care Health Dev; 2014 May; 40(3):301-8. PubMed ID: 23445484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Australian national trends in stimulant dispensing: 2002-2009.
    Hollingworth SA; Nissen LM; Stathis SS; Siskind DJ; Varghese JM; Scott JG
    Aust N Z J Psychiatry; 2011 Apr; 45(4):332-6. PubMed ID: 21184644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Licit and illicit use of medications for Attention-Deficit Hyperactivity Disorder in undergraduate college students.
    Advokat CD; Guidry D; Martino L
    J Am Coll Health; 2008; 56(6):601-6. PubMed ID: 18477513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence and belief in attention deficit hyperactivity disorder. Reintroduction of methylphenidate in Italy needs careful monitoring.
    Bonati M; Impicciatore P; Pandolfini C
    BMJ; 2001 Mar; 322(7285):556. PubMed ID: 11263458
    [No Abstract]   [Full Text] [Related]  

  • 20. Stimulants for kids with ADHD--how to proceed safely.
    Ken Mehta S; Jacobs I
    J Fam Pract; 2014 Feb; 63(2):E1-5. PubMed ID: 24527478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.